Abstract
Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.
Keywords: Anti-CD20 monoclonal antibody; COVID-19; Casirivimab/imdevimab; Neutralizing monoclonal antibody; Relapse; Rituximab.
All Keywords
【저자키워드】 COVID-19, rituximab, Anti-CD20 monoclonal antibody, casirivimab/imdevimab, neutralizing monoclonal antibody, Relapse, 【초록키워드】 Neutralizing antibodies, monoclonal antibody, immunodeficiency, Prophylactic, rituximab, therapeutic, Patient, anti-CD20, monoclonal antibody treatment, monoclonal, COVID-19 patient, humoral, treated, with COVID-19, 【제목키워드】 neutralizing antibody, anti-spike monoclonal antibody, anti-CD20 treatment, ENhance,
【저자키워드】 COVID-19, rituximab, Anti-CD20 monoclonal antibody, casirivimab/imdevimab, neutralizing monoclonal antibody, Relapse, 【초록키워드】 Neutralizing antibodies, monoclonal antibody, immunodeficiency, Prophylactic, rituximab, therapeutic, Patient, anti-CD20, monoclonal antibody treatment, monoclonal, COVID-19 patient, humoral, treated, with COVID-19, 【제목키워드】 neutralizing antibody, anti-spike monoclonal antibody, anti-CD20 treatment, ENhance,
{{{ 추상적인 }}}
체액성 면역결핍증이 있는 COVID-19 환자의 관리는 어렵습니다. 우리는 항-CD20 단일클론 항체 치료로 인해 다발성 재발이 있는 COVID-19에 걸린 여성에 대해 설명합니다. 그녀는 카시리비맙/임데비맙으로 성공적으로 치료되었고 중화 항체가 있는 것으로 확인되었습니다. 이 증례는 체액성 면역결핍증 환자에서 모노클로날 항체가 치료 및 예방적 가치가 있음을 시사합니다.
{{ 키워드: }} 항-CD20 단일클론항체; 코로나바이러스감염증-19 : 코로나19; 카시리비맙/임데비맙; 중화 모노클로날 항체; 재발; 리툭시맙.